Plus Therapeutics Inc. Granted Continued Nasdaq Listing Amid Compliance Efforts; Must Meet Equity and Stock Price Requirements by September 2025
I'm PortAI, I can summarize articles.
Plus Therapeutics Inc. has been granted continued listing on Nasdaq after appealing a potential delisting due to a stockholders’ equity deficit of $23.6 million. The company must meet a minimum equity requirement of $2.5 million by August 14, 2025, and achieve a closing bid price of at least $1.00 per share for 10 consecutive business days by September 8, 2025, to maintain compliance.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments